Candida auris (Saccharomycetaceae) is an emerging multidrug resistant fungal pathogen. The isolates are resistant to: fluconazole, amphotericin B, and echinocandins. The ecological niches for this fungus remain unidentified. However, the survival and persistence ability on dry surfaces and within hospital environments may contribute to the prevalence and outbreaks of C. auris worldwide. Several factors are related to the high virulence of C. auris, such as the multidrug resistance, biofilm development, production of phospholipases and proteinases and the ability to escape the response of the innate immune system. Since the first report of C. auris infection in Japan in 2009, this fungus has been isolated from cases on all continents. C. auris can be transmitted between patients in healthcare settings and cause healthcare-associated outbreaks. It can colonize patients, especially on the skin, perhaps indefinitely, and persist for weeks in the healthcare environment. Hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris from close contact with C. auris infected individuals, their environment, or the equipment used on colonized patients, often with fatal consequences. The crude in hospital mortality rate for C. auris candidemia is estimated to range from 30 to 72%. In most cases, clinical presentation is non-specific and it is often difficult to differentiate between other types of systemic infections. including bloodstream infections, urinary tract infection, otitis, surgical wound infections, skin abscesses. Micafungin, echinocandin drug, has been recommended as the first-line treatment for C. auris infections in adults, neonates and infants. We review the global emergence, biology, laboratory identification, drug resistance, clinical manifestations, treatment, risk factors for infection, and transmission of C. auris.